CP
MDXH icon

Castleview Partners’s MDxHealth MDXH Stock Holding History

Castleview Partners’s Portfolio MDXH Stock Details MDXH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-32,594
Closed -$72K – 190
2025
Q2 		$72K Sell
32,594
-1,182
-3% -$2.22K 0.05% 170
2025
Q1 		$48K Buy
+33,776
New +$61K 0.03% 175

Other funds holding MDXH

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
MP
MVM Partners Boston, Massachusetts $10.8M AUM 61.97% 1-Year Est. Return
SM
Samjo Management New York $231M AUM 13.04% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
FL
FreeGulliver LLC New Orleans, Louisiana $284M AUM 24.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

Castleview Partners's MDXH Position: Q3 2025 in Review

Castleview Partners sold out of MDxHealth (MDXH) in Q3 2025, closing a stake of 32,594 shares — an estimated $72K sold.

Castleview Partners first reported a position in MDXH in Q1 2025 and held it in 2 quarters. The position peaked at $72K in Q2 2025. 42 funds tracked by Wall St. Rank hold MDXH as of Q3 2025.

  • Castleview Partners reported no remaining MDxHealth position as of Q3 2025 after selling out during the quarter.
  • Castleview Partners sold 32,594 MDxHealth shares in Q3 2025, an estimated $72K.
  • Castleview Partners first reported a position in MDxHealth in Q1 2025 and held it in 2 quarters.
  • Castleview Partners's MDxHealth position peaked at $72K in Q2 2025.
  • 42 funds tracked by Wall St. Rank held MDxHealth as of Q3 2025.

Based on Castleview Partners's 13F filing for Q3 2025, filed 10 Oct 2025.